T-cell immunotherapy company Atara Biotherapeutics (Nasdaq: ATRA) closed 41% lower on Friday.

German family-owned pharma major Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical ...

Orna Therapeutics and Shanghai Simnova expand their collaboration to develop RNA-based therapies targeting BCMA for multiple ...

The FDA grants AstraZeneca’s Calquence full approval for first-line mantle cell lymphoma as a combination therapy and ...

China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) of limertinib for the ...

Even as the global diabetes war continues to rage, Indian pharmaceutical companies are emerging from the shadows, armed with ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today, approved Livdelzi (seladelpar), developed by ...

The neuromuscular disease therapeutics market is projected to grow by $13.7B from 2025 to 2029, driven by advancements in AI, ...

Despite the strategies and programs that have been implemented to bring effective and equitable access to new medicines and ...

Servier and Google Cloud expand their partnership to integrate AI and generative AI in drug R&D, focusing on rare diseases.

US health systems and Regeneron Genetics Center launch the Truveta Genome Project, a $320M initiative to sequence up to 10M ...

This executive interview, sponsored by BeiGene, is with Jan-Henrik Terwey, Vice President, Medical Affairs Europe at BeiGene.